At its meeting on 1 August 2022 the Transparency Council adopted Position No. 69/2022 on the evaluation of the drug Suliqua (insulinum glarginum + lixisenatidum) for the indication: treatment of adult patients with uncontrolled type 2 diabetes despite treatment with basal insulin (BI) in combination with at least one oral hypoglycaemic drug (OAD) with HbA1c >7%.